West Pharmaceutical reports Q1 adjusted EPS $1.56, consensus $1.26

Reports Q1 revenue $695.4M, consensus $670.3M. “We had a solid start to the year and our full-year 2024 financial outlook remains unchanged,” said Eric Green, president, CEO and chair of the board of directors. “We are actively managing the timing of inventory decisions by some of our customers, and our recent order trends reinforce our prior outlook for stronger organic sales growth in the second half of the year. As we navigate the near-term headwinds, we are controlling our costs while making strategic investments in new manufacturing capacity in both our Contract Manufacturing segment and our Proprietary Products segment, which positions us well for future organic sales growth.”